Literature DB >> 29497000

A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.

Rasmus K Jensen1, Rasmus Pihl2, Trine A F Gadeberg1, Jan K Jensen1, Kasper R Andersen1, Steffen Thiel2, Nick S Laursen1, Gregers R Andersen3.   

Abstract

The complement system is a complex, carefully regulated proteolytic cascade for which suppression of aberrant activation is of increasing clinical relevance, and inhibition of the complement alternative pathway is a subject of intense research. Here, we describe the nanobody hC3Nb1 that binds to multiple functional states of C3 with subnanomolar affinity. The nanobody causes a complete shutdown of alternative pathway activity in human and murine serum when present in concentrations comparable with that of C3, and hC3Nb1 is shown to prevent proconvertase assembly, as well as binding of the C3 substrate to C3 convertases. Our crystal structure of the C3b-hC3Nb1 complex and functional experiments demonstrate that proconvertase formation is blocked by steric hindrance between the nanobody and an Asn-linked glycan on complement factor B. In addition, hC3Nb1 is shown to prevent factor H binding to C3b, rationalizing its inhibition of factor I activity. Our results identify hC3Nb1 as a versatile, inexpensive, and powerful inhibitor of the alternative pathway in both human and murine in vitro model systems of complement activation.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  alternative pathway; antibody; complement; convertase; inhibitor; innate immunity; structural biology

Mesh:

Substances:

Year:  2018        PMID: 29497000      PMCID: PMC5925797          DOI: 10.1074/jbc.RA117.001179

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  EMAN: semiautomated software for high-resolution single-particle reconstructions.

Authors:  S J Ludtke; P R Baldwin; W Chiu
Journal:  J Struct Biol       Date:  1999-12-01       Impact factor: 2.867

Review 2.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

3.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

Review 4.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

5.  Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.

Authors:  Janus Asbjørn Schatz-Jakobsen; Yuchun Zhang; Krista Johnson; Alyssa Neill; Douglas Sheridan; Gregers Rom Andersen
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

8.  C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.

Authors:  Z Fishelson; H J Müller-Eberhard
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

9.  Structural basis for engagement by complement factor H of C3b on a self surface.

Authors:  Hugh P Morgan; Christoph Q Schmidt; Mara Guariento; Bärbel S Blaum; Dominic Gillespie; Andrew P Herbert; David Kavanagh; Haydyn D T Mertens; Dmitri I Svergun; Conny M Johansson; Dušan Uhrín; Paul N Barlow; Jonathan P Hannan
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

Review 10.  Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Authors:  Murli Krishna; Steven G Nadler
Journal:  Front Immunol       Date:  2016-02-02       Impact factor: 7.561

View more
  12 in total

1.  A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.

Authors:  Henrik Pedersen; Rasmus K Jensen; Annette G Hansen; Trine A F Gadeberg; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

2.  Complement activation by human IgG antibodies to galactose-α-1,3-galactose.

Authors:  Jens Magnus Bernth Jensen; Nick Stub Laursen; Rasmus Kjeldsen Jensen; Gregers Rom Andersen; Jens Christian Jensenius; Uffe B Skov Sørensen; Steffen Thiel
Journal:  Immunology       Date:  2020-07-14       Impact factor: 7.397

3.  The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains.

Authors:  Alice Hawkins; Callum Joyce; Kevin Brady; Adam Hold; Alan Smith; Michael Knight; Conor Howard; Jean van den Elsen; Alastair D G Lawson; Alex Macpherson
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

4.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

5.  The human natural anti-αGal antibody targets common pathogens by broad-spectrum polyreactivity.

Authors:  Jens Magnus Bernth Jensen; Sune Skeldal; Mikkel Steen Petersen; Bjarne Kuno Møller; Steen Hoffmann; Jens Christian Jensenius; Uffe B Skov Sørensen; Steffen Thiel
Journal:  Immunology       Date:  2021-01-04       Impact factor: 7.397

6.  Properdin oligomers adopt rigid extended conformations supporting function.

Authors:  Dennis V Pedersen; Martin Nors Pedersen; Sofia Mm Mazarakis; Yong Wang; Kresten Lindorff-Larsen; Lise Arleth; Gregers R Andersen
Journal:  Elife       Date:  2021-01-22       Impact factor: 8.140

Review 7.  Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies.

Authors:  Alessandra Zarantonello; Henrik Pedersen; Nick S Laursen; Gregers R Andersen
Journal:  Biomolecules       Date:  2021-02-17

8.  ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism.

Authors:  Rasmus Pihl; Rasmus K Jensen; Emil C Poulsen; Lisbeth Jensen; Annette G Hansen; Ida B Thøgersen; József Dobó; Péter Gál; Gregers R Andersen; Jan J Enghild; Steffen Thiel
Journal:  Sci Adv       Date:  2021-01-08       Impact factor: 14.136

9.  Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.

Authors:  Nick S Laursen; Dennis V Pedersen; Heidi Gytz; Alessandra Zarantonello; Jens Magnus Bernth Jensen; Annette G Hansen; Steffen Thiel; Gregers R Andersen
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

10.  Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.

Authors:  Dennis V Pedersen; Trine A F Gadeberg; Caroline Thomas; Yong Wang; Nicolas Joram; Rasmus K Jensen; Sofia M M Mazarakis; Margot Revel; Carine El Sissy; Steen V Petersen; Kresten Lindorff-Larsen; Steffen Thiel; Nick S Laursen; Véronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.